| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 215 | 2024 | 764 | 27.270 |
Why?
|
| Colitis, Ulcerative | 175 | 2024 | 760 | 20.460 |
Why?
|
| Inflammatory Bowel Diseases | 83 | 2024 | 594 | 15.650 |
Why?
|
| Gastrointestinal Agents | 53 | 2024 | 174 | 10.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 48 | 2021 | 244 | 6.860 |
Why?
|
| Anti-Inflammatory Agents | 50 | 2020 | 346 | 6.610 |
Why?
|
| Immunosuppressive Agents | 65 | 2021 | 979 | 6.590 |
Why?
|
| Antibodies, Monoclonal | 71 | 2024 | 1396 | 6.500 |
Why?
|
| Mesalamine | 45 | 2020 | 88 | 6.460 |
Why?
|
| Gastroenterology | 14 | 2020 | 147 | 4.450 |
Why?
|
| Remission Induction | 77 | 2024 | 741 | 3.970 |
Why?
|
| Infliximab | 53 | 2024 | 159 | 3.780 |
Why?
|
| Tumor Necrosis Factor-alpha | 43 | 2023 | 700 | 3.730 |
Why?
|
| Humans | 487 | 2024 | 90014 | 3.650 |
Why?
|
| Biological Therapy | 16 | 2020 | 47 | 3.570 |
Why?
|
| Biosimilar Pharmaceuticals | 5 | 2024 | 25 | 3.540 |
Why?
|
| Colitis | 13 | 2024 | 247 | 3.460 |
Why?
|
| Biological Products | 13 | 2023 | 161 | 3.320 |
Why?
|
| Azathioprine | 22 | 2021 | 124 | 3.150 |
Why?
|
| Adalimumab | 23 | 2024 | 89 | 2.940 |
Why?
|
| Treatment Outcome | 129 | 2024 | 8292 | 2.920 |
Why?
|
| Immunologic Factors | 14 | 2021 | 171 | 2.850 |
Why?
|
| Severity of Illness Index | 64 | 2024 | 1863 | 2.730 |
Why?
|
| Aminosalicylic Acids | 29 | 2016 | 41 | 2.700 |
Why?
|
| Double-Blind Method | 84 | 2024 | 1714 | 2.570 |
Why?
|
| Stress Disorders, Post-Traumatic | 5 | 2023 | 115 | 2.380 |
Why?
|
| Adrenal Cortex Hormones | 26 | 2024 | 272 | 2.280 |
Why?
|
| Mercaptopurine | 13 | 2018 | 53 | 2.250 |
Why?
|
| Adult | 198 | 2024 | 26836 | 2.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 38 | 2024 | 952 | 2.010 |
Why?
|
| Female | 216 | 2024 | 46617 | 1.850 |
Why?
|
| Male | 205 | 2024 | 42705 | 1.810 |
Why?
|
| Sulfasalazine | 18 | 2016 | 34 | 1.780 |
Why?
|
| Clinical Trials as Topic | 24 | 2024 | 1134 | 1.760 |
Why?
|
| Maintenance Chemotherapy | 14 | 2024 | 84 | 1.750 |
Why?
|
| Glucocorticoids | 20 | 2024 | 358 | 1.740 |
Why?
|
| Colonoscopy | 24 | 2021 | 281 | 1.730 |
Why?
|
| Ustekinumab | 9 | 2023 | 52 | 1.730 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2023 | 171 | 1.720 |
Why?
|
| Intestinal Mucosa | 25 | 2020 | 806 | 1.710 |
Why?
|
| Methotrexate | 12 | 2022 | 243 | 1.700 |
Why?
|
| Colorectal Neoplasms | 15 | 2024 | 980 | 1.670 |
Why?
|
| Middle Aged | 150 | 2024 | 26173 | 1.630 |
Why?
|
| Drug Therapy, Combination | 27 | 2023 | 785 | 1.620 |
Why?
|
| Pharmaceutical Preparations | 3 | 2021 | 92 | 1.590 |
Why?
|
| Induction Chemotherapy | 12 | 2023 | 152 | 1.530 |
Why?
|
| Cyclosporine | 13 | 2018 | 238 | 1.510 |
Why?
|
| Smoking | 15 | 2020 | 625 | 1.480 |
Why?
|
| Colectomy | 22 | 2018 | 175 | 1.470 |
Why?
|
| Digestive System Diseases | 6 | 2010 | 18 | 1.430 |
Why?
|
| Diarrhea | 9 | 2021 | 178 | 1.330 |
Why?
|
| Drug Monitoring | 8 | 2020 | 118 | 1.330 |
Why?
|
| Biomedical Research | 7 | 2010 | 405 | 1.330 |
Why?
|
| Fellowships and Scholarships | 2 | 2020 | 126 | 1.280 |
Why?
|
| Randomized Controlled Trials as Topic | 23 | 2024 | 841 | 1.190 |
Why?
|
| Drug Industry | 4 | 2009 | 54 | 1.190 |
Why?
|
| Pyrimidines | 2 | 2021 | 371 | 1.140 |
Why?
|
| Colon | 25 | 2020 | 521 | 1.110 |
Why?
|
| Secondary Prevention | 9 | 2020 | 159 | 1.110 |
Why?
|
| Nicotine | 8 | 2012 | 200 | 1.110 |
Why?
|
| Education, Medical, Graduate | 2 | 2020 | 403 | 1.060 |
Why?
|
| United States | 37 | 2024 | 7114 | 1.050 |
Why?
|
| Quality of Life | 26 | 2024 | 1682 | 1.020 |
Why?
|
| Budesonide | 10 | 2016 | 46 | 1.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2022 | 201 | 1.020 |
Why?
|
| Immunoglobulin Fab Fragments | 10 | 2014 | 85 | 1.010 |
Why?
|
| Anti-Infective Agents | 8 | 2013 | 91 | 0.980 |
Why?
|
| Serum | 2 | 2015 | 25 | 0.980 |
Why?
|
| Vitamin D | 4 | 2016 | 269 | 0.970 |
Why?
|
| Dose-Response Relationship, Drug | 38 | 2022 | 1929 | 0.960 |
Why?
|
| Evidence-Based Medicine | 8 | 2011 | 435 | 0.950 |
Why?
|
| Certolizumab Pegol | 11 | 2016 | 19 | 0.950 |
Why?
|
| Safety | 9 | 2021 | 145 | 0.950 |
Why?
|
| Loperamide | 4 | 2008 | 7 | 0.940 |
Why?
|
| Anti-Bacterial Agents | 15 | 2011 | 799 | 0.940 |
Why?
|
| Drug Administration Schedule | 23 | 2020 | 865 | 0.930 |
Why?
|
| Antidiarrheals | 4 | 2008 | 14 | 0.930 |
Why?
|
| Biomarkers | 14 | 2024 | 1778 | 0.920 |
Why?
|
| Polyethylene Glycols | 10 | 2014 | 360 | 0.900 |
Why?
|
| Health Care Reform | 3 | 2010 | 85 | 0.890 |
Why?
|
| Semen | 2 | 2022 | 13 | 0.870 |
Why?
|
| Allopurinol | 5 | 2018 | 77 | 0.870 |
Why?
|
| Travel | 3 | 2010 | 72 | 0.870 |
Why?
|
| Drug Resistance | 13 | 2014 | 232 | 0.850 |
Why?
|
| Irritable Bowel Syndrome | 3 | 2008 | 46 | 0.850 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2023 | 23 | 0.850 |
Why?
|
| Nicotinic Agonists | 3 | 2012 | 74 | 0.830 |
Why?
|
| Semen Analysis | 1 | 2022 | 2 | 0.820 |
Why?
|
| Risk Assessment | 13 | 2019 | 2327 | 0.820 |
Why?
|
| Practice Guidelines as Topic | 11 | 2016 | 1055 | 0.820 |
Why?
|
| Piperidines | 3 | 2021 | 163 | 0.810 |
Why?
|
| Aged | 71 | 2024 | 19272 | 0.810 |
Why?
|
| Placebos | 12 | 2018 | 211 | 0.800 |
Why?
|
| Atrioventricular Block | 1 | 2022 | 25 | 0.790 |
Why?
|
| Europe | 9 | 2023 | 324 | 0.770 |
Why?
|
| Diet, Mediterranean | 1 | 2021 | 5 | 0.760 |
Why?
|
| Oxadiazoles | 5 | 2024 | 38 | 0.760 |
Why?
|
| Indans | 5 | 2024 | 35 | 0.760 |
Why?
|
| Gastrointestinal Diseases | 4 | 2024 | 151 | 0.750 |
Why?
|
| Pyrroles | 2 | 2021 | 172 | 0.750 |
Why?
|
| Prodrugs | 4 | 2013 | 52 | 0.750 |
Why?
|
| Young Adult | 37 | 2024 | 6418 | 0.740 |
Why?
|
| Colonic Neoplasms | 11 | 2018 | 572 | 0.740 |
Why?
|
| Injections, Subcutaneous | 9 | 2024 | 122 | 0.730 |
Why?
|
| Adolescent | 55 | 2021 | 9347 | 0.730 |
Why?
|
| Recurrence | 22 | 2020 | 1147 | 0.720 |
Why?
|
| Time Factors | 34 | 2024 | 5361 | 0.720 |
Why?
|
| Steroids | 12 | 2011 | 173 | 0.710 |
Why?
|
| Patient Selection | 8 | 2011 | 682 | 0.710 |
Why?
|
| Diagnostic Imaging | 4 | 2014 | 476 | 0.710 |
Why?
|
| Competency-Based Education | 1 | 2020 | 38 | 0.700 |
Why?
|
| C-Reactive Protein | 14 | 2022 | 192 | 0.700 |
Why?
|
| Precancerous Conditions | 4 | 2016 | 201 | 0.690 |
Why?
|
| Global Health | 5 | 2011 | 193 | 0.690 |
Why?
|
| Psychopathology | 1 | 2019 | 30 | 0.670 |
Why?
|
| alpha-Fetoproteins | 1 | 2019 | 44 | 0.650 |
Why?
|
| Diet | 4 | 2021 | 444 | 0.650 |
Why?
|
| Antibodies | 10 | 2016 | 353 | 0.650 |
Why?
|
| Administration, Oral | 18 | 2016 | 667 | 0.650 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 124 | 0.650 |
Why?
|
| Gastrointestinal Tract | 2 | 2014 | 192 | 0.620 |
Why?
|
| Conflict of Interest | 3 | 2009 | 68 | 0.610 |
Why?
|
| Purines | 1 | 2018 | 93 | 0.600 |
Why?
|
| Follow-Up Studies | 22 | 2019 | 3684 | 0.600 |
Why?
|
| Chronic Disease | 10 | 2022 | 958 | 0.600 |
Why?
|
| Health Care Costs | 3 | 2009 | 236 | 0.590 |
Why?
|
| Primary Prevention | 2 | 2008 | 82 | 0.570 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 204 | 0.570 |
Why?
|
| Vitamin D Deficiency | 3 | 2016 | 104 | 0.550 |
Why?
|
| Ulcer | 3 | 2006 | 37 | 0.550 |
Why?
|
| Interleukin-23 | 1 | 2017 | 57 | 0.550 |
Why?
|
| Anti-Ulcer Agents | 4 | 2005 | 22 | 0.540 |
Why?
|
| Prognosis | 20 | 2020 | 3800 | 0.540 |
Why?
|
| Drug Approval | 2 | 2007 | 65 | 0.540 |
Why?
|
| Food | 3 | 2021 | 89 | 0.540 |
Why?
|
| Risk Factors | 22 | 2021 | 5562 | 0.540 |
Why?
|
| Sigmoidoscopy | 11 | 2015 | 36 | 0.530 |
Why?
|
| Cholangitis, Sclerosing | 5 | 2020 | 51 | 0.530 |
Why?
|
| Enema | 7 | 2008 | 39 | 0.520 |
Why?
|
| Gastrointestinal Hemorrhage | 4 | 2020 | 239 | 0.520 |
Why?
|
| Trichuris | 2 | 2013 | 2 | 0.520 |
Why?
|
| Proctocolectomy, Restorative | 2 | 2012 | 105 | 0.510 |
Why?
|
| Enterocolitis | 2 | 2022 | 13 | 0.500 |
Why?
|
| Wound Healing | 8 | 2020 | 362 | 0.490 |
Why?
|
| Granulocytes | 2 | 2012 | 38 | 0.490 |
Why?
|
| Blood Component Removal | 2 | 2012 | 24 | 0.480 |
Why?
|
| Infusions, Intravenous | 15 | 2016 | 416 | 0.470 |
Why?
|
| Academic Medical Centers | 2 | 2009 | 385 | 0.470 |
Why?
|
| Delayed-Action Preparations | 9 | 2016 | 110 | 0.470 |
Why?
|
| Pneumonia | 2 | 2015 | 183 | 0.460 |
Why?
|
| History, 20th Century | 5 | 2012 | 315 | 0.460 |
Why?
|
| Metabolic Syndrome | 2 | 2006 | 123 | 0.460 |
Why?
|
| Patient Satisfaction | 5 | 2011 | 462 | 0.460 |
Why?
|
| Clinical Competence | 3 | 2020 | 797 | 0.460 |
Why?
|
| Monocytes | 4 | 2012 | 221 | 0.450 |
Why?
|
| Delivery of Health Care | 2 | 2009 | 437 | 0.450 |
Why?
|
| Diverticulitis | 1 | 2013 | 10 | 0.450 |
Why?
|
| Societies, Medical | 2 | 2015 | 584 | 0.450 |
Why?
|
| Research Design | 7 | 2024 | 591 | 0.440 |
Why?
|
| Intestinal Polyps | 2 | 2008 | 27 | 0.440 |
Why?
|
| Therapy with Helminths | 1 | 2013 | 1 | 0.440 |
Why?
|
| Antigens, Helminth | 1 | 2013 | 22 | 0.440 |
Why?
|
| Tacrolimus | 3 | 2011 | 369 | 0.430 |
Why?
|
| Diverticulum | 1 | 2013 | 45 | 0.430 |
Why?
|
| Ovum | 1 | 2013 | 59 | 0.430 |
Why?
|
| Life Style | 3 | 2008 | 176 | 0.420 |
Why?
|
| Ileostomy | 3 | 2012 | 29 | 0.420 |
Why?
|
| Antimetabolites | 4 | 2011 | 24 | 0.420 |
Why?
|
| Thioguanine | 5 | 2018 | 17 | 0.420 |
Why?
|
| Treatment Refusal | 3 | 2011 | 62 | 0.420 |
Why?
|
| Obesity | 4 | 2008 | 972 | 0.410 |
Why?
|
| Hospitalization | 6 | 2024 | 888 | 0.410 |
Why?
|
| Radiation Injuries | 2 | 2014 | 161 | 0.410 |
Why?
|
| Disease Progression | 7 | 2024 | 1469 | 0.400 |
Why?
|
| Population Surveillance | 5 | 2016 | 216 | 0.400 |
Why?
|
| Allergens | 1 | 2013 | 183 | 0.400 |
Why?
|
| Surgical Stomas | 1 | 2012 | 22 | 0.400 |
Why?
|
| Postoperative Complications | 8 | 2018 | 2316 | 0.400 |
Why?
|
| Carnitine | 1 | 2012 | 14 | 0.400 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 1545 | 0.400 |
Why?
|
| Colonic Polyps | 2 | 2018 | 132 | 0.400 |
Why?
|
| Intestinal Fistula | 5 | 2016 | 31 | 0.390 |
Why?
|
| History, 21st Century | 4 | 2012 | 185 | 0.390 |
Why?
|
| Colonic Diseases, Functional | 3 | 2003 | 3 | 0.380 |
Why?
|
| Biological Factors | 3 | 2019 | 18 | 0.380 |
Why?
|
| Health Promotion | 3 | 2008 | 165 | 0.370 |
Why?
|
| Vitamins | 2 | 2016 | 83 | 0.370 |
Why?
|
| Pregnancy | 12 | 2019 | 3046 | 0.370 |
Why?
|
| Disease Outbreaks | 2 | 2009 | 156 | 0.360 |
Why?
|
| Biopsy | 11 | 2020 | 1184 | 0.360 |
Why?
|
| Endoscopy, Gastrointestinal | 7 | 2013 | 163 | 0.360 |
Why?
|
| Physicians | 2 | 2009 | 692 | 0.360 |
Why?
|
| Neutrophils | 3 | 2024 | 311 | 0.360 |
Why?
|
| Case-Control Studies | 16 | 2023 | 1868 | 0.360 |
Why?
|
| Inflammation | 7 | 2023 | 981 | 0.360 |
Why?
|
| Hypertension, Portal | 1 | 2010 | 46 | 0.360 |
Why?
|
| Leukapheresis | 3 | 2008 | 20 | 0.350 |
Why?
|
| Otitis Media | 1 | 2010 | 20 | 0.350 |
Why?
|
| Cephalosporins | 1 | 2010 | 24 | 0.350 |
Why?
|
| Health Behavior | 2 | 2009 | 185 | 0.350 |
Why?
|
| Prednisolone | 3 | 2018 | 40 | 0.340 |
Why?
|
| Education, Medical, Continuing | 2 | 2011 | 106 | 0.340 |
Why?
|
| Peptic Ulcer | 1 | 2009 | 18 | 0.330 |
Why?
|
| Self Disclosure | 1 | 2009 | 32 | 0.330 |
Why?
|
| Proctitis | 2 | 2000 | 12 | 0.330 |
Why?
|
| Esophagitis | 1 | 2009 | 43 | 0.330 |
Why?
|
| Safety Management | 1 | 2009 | 56 | 0.330 |
Why?
|
| Specialization | 1 | 2010 | 70 | 0.330 |
Why?
|
| Outsourced Services | 1 | 2009 | 1 | 0.330 |
Why?
|
| Consumer Product Safety | 1 | 2009 | 11 | 0.330 |
Why?
|
| Commerce | 1 | 2009 | 31 | 0.330 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 34 | 0.330 |
Why?
|
| Body Temperature Regulation | 1 | 2009 | 56 | 0.330 |
Why?
|
| Financial Support | 1 | 2009 | 7 | 0.330 |
Why?
|
| Food Contamination | 1 | 2009 | 34 | 0.320 |
Why?
|
| Food Supply | 1 | 2009 | 29 | 0.320 |
Why?
|
| Uncertainty | 2 | 2021 | 76 | 0.320 |
Why?
|
| Adipose Tissue, Brown | 1 | 2009 | 86 | 0.320 |
Why?
|
| Sulfapyridine | 1 | 2008 | 2 | 0.310 |
Why?
|
| Abdominal Pain | 2 | 2007 | 142 | 0.310 |
Why?
|
| Muscle Hypotonia | 1 | 2009 | 49 | 0.310 |
Why?
|
| Jet Lag Syndrome | 1 | 2008 | 13 | 0.310 |
Why?
|
| Drug Delivery Systems | 2 | 2007 | 178 | 0.310 |
Why?
|
| Surveys and Questionnaires | 11 | 2019 | 2658 | 0.300 |
Why?
|
| Happiness | 1 | 2008 | 12 | 0.300 |
Why?
|
| Histamine Antagonists | 1 | 2008 | 13 | 0.300 |
Why?
|
| Task Performance and Analysis | 1 | 2008 | 87 | 0.300 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 168 | 0.300 |
Why?
|
| Self Efficacy | 1 | 2008 | 57 | 0.300 |
Why?
|
| Prospective Studies | 20 | 2024 | 4329 | 0.300 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 97 | 0.300 |
Why?
|
| Marketing | 1 | 2008 | 23 | 0.300 |
Why?
|
| Prevalence | 6 | 2022 | 1250 | 0.300 |
Why?
|
| Prednisone | 8 | 2007 | 255 | 0.300 |
Why?
|
| Legislation as Topic | 1 | 2007 | 3 | 0.300 |
Why?
|
| Behavior | 1 | 2008 | 85 | 0.300 |
Why?
|
| Fasting | 1 | 2008 | 162 | 0.300 |
Why?
|
| Ileal Diseases | 2 | 2004 | 26 | 0.290 |
Why?
|
| Immunity, Innate | 2 | 2014 | 434 | 0.290 |
Why?
|
| Retrospective Studies | 24 | 2020 | 9237 | 0.290 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 467 | 0.290 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2007 | 7 | 0.290 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2008 | 152 | 0.290 |
Why?
|
| Neoplasms | 5 | 2024 | 3067 | 0.290 |
Why?
|
| Antirheumatic Agents | 4 | 2011 | 58 | 0.290 |
Why?
|
| Feces | 4 | 2021 | 333 | 0.290 |
Why?
|
| Gastroesophageal Reflux | 1 | 2009 | 125 | 0.290 |
Why?
|
| Simethicone | 1 | 2007 | 1 | 0.290 |
Why?
|
| Flatulence | 1 | 2007 | 2 | 0.290 |
Why?
|
| Health Priorities | 1 | 2007 | 22 | 0.290 |
Why?
|
| Terminology as Topic | 2 | 2011 | 222 | 0.290 |
Why?
|
| Retreatment | 5 | 2016 | 107 | 0.290 |
Why?
|
| Gastrointestinal Motility | 1 | 2007 | 25 | 0.290 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2007 | 27 | 0.280 |
Why?
|
| Quality of Health Care | 2 | 2012 | 387 | 0.280 |
Why?
|
| Diagnosis, Differential | 8 | 2010 | 1606 | 0.280 |
Why?
|
| Liver Diseases | 2 | 2008 | 242 | 0.280 |
Why?
|
| Energy Metabolism | 1 | 2009 | 282 | 0.280 |
Why?
|
| Nutrition Assessment | 1 | 2007 | 20 | 0.280 |
Why?
|
| Economic Competition | 1 | 2006 | 12 | 0.280 |
Why?
|
| Patents as Topic | 1 | 2006 | 12 | 0.280 |
Why?
|
| Insemination, Artificial, Homologous | 1 | 2006 | 4 | 0.280 |
Why?
|
| Immunity | 1 | 2008 | 141 | 0.280 |
Why?
|
| Ethics, Medical | 1 | 2009 | 306 | 0.270 |
Why?
|
| Ovulation Induction | 1 | 2006 | 31 | 0.270 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2006 | 30 | 0.270 |
Why?
|
| Abdominal Abscess | 2 | 2016 | 23 | 0.270 |
Why?
|
| Drugs, Generic | 1 | 2006 | 21 | 0.270 |
Why?
|
| Biodiversity | 1 | 2009 | 209 | 0.270 |
Why?
|
| Occupational Health | 1 | 2007 | 36 | 0.270 |
Why?
|
| United States Food and Drug Administration | 1 | 2007 | 135 | 0.270 |
Why?
|
| Observation | 1 | 2006 | 38 | 0.270 |
Why?
|
| Nobel Prize | 1 | 2006 | 10 | 0.270 |
Why?
|
| Health Expenditures | 1 | 2007 | 90 | 0.270 |
Why?
|
| Autistic Disorder | 1 | 2007 | 147 | 0.270 |
Why?
|
| Infertility | 1 | 2006 | 35 | 0.270 |
Why?
|
| Contraceptives, Oral | 3 | 1991 | 46 | 0.270 |
Why?
|
| Self Concept | 1 | 2007 | 135 | 0.260 |
Why?
|
| Pandemics | 2 | 2022 | 778 | 0.260 |
Why?
|
| Integrins | 3 | 2021 | 78 | 0.260 |
Why?
|
| Disease Management | 4 | 2018 | 327 | 0.260 |
Why?
|
| Ileum | 7 | 2016 | 168 | 0.260 |
Why?
|
| Vibrio Infections | 1 | 2005 | 2 | 0.260 |
Why?
|
| Thiazoles | 1 | 2006 | 127 | 0.260 |
Why?
|
| Genetics | 1 | 2006 | 24 | 0.260 |
Why?
|
| Natalizumab | 7 | 2013 | 21 | 0.260 |
Why?
|
| Gastroenteritis | 1 | 2005 | 26 | 0.250 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 450 | 0.250 |
Why?
|
| Private Practice | 1 | 2005 | 11 | 0.250 |
Why?
|
| Climate | 1 | 2005 | 58 | 0.250 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 303 | 0.250 |
Why?
|
| Spermatozoa | 2 | 2022 | 62 | 0.250 |
Why?
|
| Symptom Assessment | 3 | 2020 | 67 | 0.250 |
Why?
|
| Ethics Committees, Research | 1 | 2005 | 34 | 0.250 |
Why?
|
| Aged, 80 and over | 12 | 2019 | 6787 | 0.250 |
Why?
|
| Intestine, Small | 6 | 2021 | 299 | 0.250 |
Why?
|
| Unemployment | 1 | 2005 | 10 | 0.250 |
Why?
|
| Foodborne Diseases | 1 | 2005 | 8 | 0.250 |
Why?
|
| Human Experimentation | 1 | 2005 | 39 | 0.250 |
Why?
|
| Researcher-Subject Relations | 1 | 2005 | 4 | 0.250 |
Why?
|
| Stress, Psychological | 1 | 2008 | 322 | 0.240 |
Why?
|
| Journalism, Medical | 1 | 2004 | 6 | 0.240 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2024 | 13 | 0.240 |
Why?
|
| Pregnancy Complications | 3 | 2004 | 344 | 0.240 |
Why?
|
| Peer Review | 1 | 2004 | 23 | 0.240 |
Why?
|
| Dietary Supplements | 1 | 2005 | 124 | 0.240 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 189 | 0.240 |
Why?
|
| Rectal Fistula | 3 | 2014 | 18 | 0.240 |
Why?
|
| HLA-DR Antigens | 1 | 2004 | 59 | 0.240 |
Why?
|
| Ultrasonography | 2 | 2018 | 720 | 0.230 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2024 | 1 | 0.230 |
Why?
|
| Ileitis | 3 | 2011 | 7 | 0.230 |
Why?
|
| Disability Evaluation | 1 | 2005 | 140 | 0.230 |
Why?
|
| Pain | 2 | 2023 | 400 | 0.230 |
Why?
|
| HLA-DQ Antigens | 1 | 2004 | 51 | 0.230 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2024 | 196 | 0.230 |
Why?
|
| Intestines | 3 | 2020 | 416 | 0.230 |
Why?
|
| Acute Disease | 9 | 2011 | 846 | 0.230 |
Why?
|
| Serum Albumin | 2 | 2019 | 128 | 0.230 |
Why?
|
| Feeding Behavior | 1 | 2007 | 328 | 0.230 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2015 | 51 | 0.230 |
Why?
|
| MicroRNAs | 4 | 2021 | 556 | 0.230 |
Why?
|
| Animals | 15 | 2024 | 27536 | 0.230 |
Why?
|
| Stents | 1 | 2007 | 412 | 0.230 |
Why?
|
| Cecal Diseases | 1 | 2003 | 5 | 0.230 |
Why?
|
| Career Choice | 1 | 2005 | 148 | 0.230 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2023 | 10 | 0.220 |
Why?
|
| Aging | 1 | 2009 | 727 | 0.220 |
Why?
|
| Enterocolitis, Pseudomembranous | 3 | 2011 | 52 | 0.220 |
Why?
|
| Osteoporosis | 1 | 2005 | 124 | 0.220 |
Why?
|
| Employment | 1 | 2004 | 53 | 0.220 |
Why?
|
| Congresses as Topic | 3 | 2010 | 115 | 0.220 |
Why?
|
| Adenocarcinoma | 3 | 2018 | 1185 | 0.220 |
Why?
|
| Lactoferrin | 1 | 2003 | 10 | 0.220 |
Why?
|
| Organ Transplantation | 1 | 2007 | 283 | 0.220 |
Why?
|
| Lupus Vulgaris | 1 | 2003 | 4 | 0.220 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2021 | 67 | 0.220 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2010 | 387 | 0.220 |
Why?
|
| Fetus | 1 | 2004 | 232 | 0.210 |
Why?
|
| Lung Diseases | 1 | 2005 | 275 | 0.210 |
Why?
|
| Fibroblast Growth Factors | 1 | 2003 | 81 | 0.210 |
Why?
|
| Adjuvants, Immunologic | 4 | 2009 | 169 | 0.210 |
Why?
|
| Placenta | 2 | 2015 | 181 | 0.210 |
Why?
|
| Adipose Tissue | 1 | 2005 | 262 | 0.210 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2018 | 171 | 0.210 |
Why?
|
| Anus Diseases | 2 | 2003 | 15 | 0.200 |
Why?
|
| Incidence | 8 | 2020 | 1604 | 0.200 |
Why?
|
| Calcineurin Inhibitors | 2 | 2013 | 53 | 0.200 |
Why?
|
| Education, Medical | 1 | 2005 | 243 | 0.200 |
Why?
|
| Pentanoic Acids | 1 | 2002 | 6 | 0.200 |
Why?
|
| Cycloserine | 1 | 2001 | 5 | 0.200 |
Why?
|
| Chicago | 4 | 2018 | 1434 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2010 | 2360 | 0.190 |
Why?
|
| Graft Rejection | 1 | 2007 | 1076 | 0.190 |
Why?
|
| DNA End-Joining Repair | 1 | 2021 | 3 | 0.190 |
Why?
|
| Carbohydrates | 1 | 2021 | 47 | 0.190 |
Why?
|
| Administration, Topical | 4 | 2016 | 96 | 0.190 |
Why?
|
| Language | 1 | 2022 | 157 | 0.190 |
Why?
|
| Interleukin-12 | 1 | 2021 | 111 | 0.190 |
Why?
|
| CD3 Complex | 3 | 2014 | 134 | 0.190 |
Why?
|
| Symptom Flare Up | 2 | 2021 | 12 | 0.180 |
Why?
|
| Cell Adhesion Molecules | 3 | 2024 | 166 | 0.180 |
Why?
|
| Mycophenolic Acid | 1 | 2001 | 84 | 0.180 |
Why?
|
| Phenylhydrazines | 5 | 2005 | 10 | 0.180 |
Why?
|
| Chemoprevention | 3 | 2006 | 92 | 0.180 |
Why?
|
| Leukocyte L1 Antigen Complex | 4 | 2023 | 48 | 0.180 |
Why?
|
| DNA | 3 | 2022 | 1311 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 358 | 0.170 |
Why?
|
| Erythrocyte Count | 1 | 2019 | 22 | 0.170 |
Why?
|
| Ipilimumab | 1 | 2020 | 60 | 0.170 |
Why?
|
| Pyridines | 1 | 2002 | 300 | 0.170 |
Why?
|
| Hematocrit | 1 | 2019 | 68 | 0.170 |
Why?
|
| Logistic Models | 5 | 2006 | 1214 | 0.170 |
Why?
|
| Erythema Nodosum | 2 | 2006 | 4 | 0.170 |
Why?
|
| Genetic Linkage | 5 | 2002 | 624 | 0.170 |
Why?
|
| Thalidomide | 1 | 1999 | 55 | 0.170 |
Why?
|
| Pouchitis | 2 | 2012 | 54 | 0.170 |
Why?
|
| Platelet Count | 1 | 2019 | 93 | 0.170 |
Why?
|
| Forecasting | 3 | 2008 | 304 | 0.170 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 140 | 0.170 |
Why?
|
| Psoriasis | 1 | 2022 | 245 | 0.160 |
Why?
|
| Indoles | 3 | 2009 | 301 | 0.160 |
Why?
|
| Neurons | 1 | 2008 | 1591 | 0.160 |
Why?
|
| Blood Proteins | 1 | 2019 | 149 | 0.160 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1999 | 111 | 0.160 |
Why?
|
| Long-Term Care | 4 | 2017 | 61 | 0.160 |
Why?
|
| Hemoglobins | 1 | 2019 | 193 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2005 | 716 | 0.160 |
Why?
|
| Rectum | 6 | 2011 | 148 | 0.150 |
Why?
|
| Treatment Failure | 4 | 2014 | 278 | 0.150 |
Why?
|
| Menstrual Cycle | 1 | 1998 | 54 | 0.150 |
Why?
|
| Genomic Instability | 1 | 2019 | 83 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 173 | 0.150 |
Why?
|
| Interleukin-6 | 2 | 2017 | 264 | 0.150 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1998 | 44 | 0.150 |
Why?
|
| Stomatitis, Aphthous | 1 | 1998 | 4 | 0.150 |
Why?
|
| Sensitivity and Specificity | 3 | 2010 | 2018 | 0.150 |
Why?
|
| Autoimmune Diseases | 2 | 2002 | 250 | 0.150 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 1747 | 0.150 |
Why?
|
| Pyoderma Gangrenosum | 1 | 1998 | 19 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 2507 | 0.150 |
Why?
|
| Fecal Incontinence | 2 | 2008 | 58 | 0.150 |
Why?
|
| Aspirin | 1 | 2019 | 162 | 0.150 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 279 | 0.150 |
Why?
|
| Child | 11 | 2013 | 7242 | 0.150 |
Why?
|
| Thrombospondins | 1 | 2017 | 14 | 0.150 |
Why?
|
| Caveolin 1 | 1 | 2017 | 21 | 0.150 |
Why?
|
| Parenteral Nutrition, Total | 4 | 2005 | 41 | 0.150 |
Why?
|
| Antibody Formation | 2 | 2011 | 171 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 1 | 1998 | 107 | 0.140 |
Why?
|
| Pilot Projects | 7 | 2013 | 872 | 0.140 |
Why?
|
| Standard of Care | 1 | 2018 | 65 | 0.140 |
Why?
|
| Colonic Diseases | 3 | 2006 | 61 | 0.140 |
Why?
|
| Paternal Exposure | 1 | 2017 | 3 | 0.140 |
Why?
|
| Cohort Studies | 4 | 2019 | 2887 | 0.140 |
Why?
|
| Meta-Analysis as Topic | 2 | 2009 | 82 | 0.140 |
Why?
|
| Collagen Type I | 1 | 2017 | 72 | 0.140 |
Why?
|
| Legislation, Drug | 2 | 2007 | 6 | 0.140 |
Why?
|
| Reproducibility of Results | 6 | 2024 | 2770 | 0.140 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 476 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2016 | 608 | 0.140 |
Why?
|
| Protein-Losing Enteropathies | 1 | 1996 | 6 | 0.140 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1998 | 154 | 0.140 |
Why?
|
| Injections, Intravenous | 4 | 2018 | 238 | 0.140 |
Why?
|
| Focal Adhesions | 1 | 2017 | 70 | 0.140 |
Why?
|
| Drug Design | 1 | 2017 | 126 | 0.140 |
Why?
|
| United Kingdom | 3 | 2020 | 165 | 0.140 |
Why?
|
| Placebo Effect | 2 | 2014 | 30 | 0.140 |
Why?
|
| Drug Synergism | 2 | 2007 | 307 | 0.140 |
Why?
|
| Fertility | 1 | 2017 | 116 | 0.140 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2014 | 13 | 0.130 |
Why?
|
| Cross-Over Studies | 3 | 2009 | 387 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 1 | 2018 | 341 | 0.130 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2016 | 37 | 0.130 |
Why?
|
| Guidelines as Topic | 2 | 2007 | 158 | 0.130 |
Why?
|
| Algorithms | 4 | 2014 | 1913 | 0.130 |
Why?
|
| Nod2 Signaling Adaptor Protein | 4 | 2010 | 13 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2020 | 522 | 0.130 |
Why?
|
| Receptors, Calcitriol | 2 | 2016 | 130 | 0.130 |
Why?
|
| Digestive System Fistula | 3 | 2010 | 4 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 281 | 0.130 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 490 | 0.130 |
Why?
|
| Transition to Adult Care | 1 | 2016 | 22 | 0.130 |
Why?
|
| Drug Combinations | 2 | 2007 | 203 | 0.130 |
Why?
|
| Smoking Cessation | 3 | 2012 | 258 | 0.130 |
Why?
|
| Chi-Square Distribution | 3 | 2007 | 359 | 0.130 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2015 | 12 | 0.130 |
Why?
|
| Clinical Medicine | 1 | 2015 | 34 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2000 | 79 | 0.120 |
Why?
|
| Integrin alpha4 | 3 | 2013 | 11 | 0.120 |
Why?
|
| Lymphocytes | 2 | 2015 | 468 | 0.120 |
Why?
|
| Monitoring, Physiologic | 3 | 2012 | 266 | 0.120 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2005 | 128 | 0.120 |
Why?
|
| T-Lymphocytes | 4 | 2023 | 1221 | 0.120 |
Why?
|
| Autoantibodies | 1 | 1996 | 270 | 0.120 |
Why?
|
| Cell Migration Inhibition | 1 | 2014 | 8 | 0.120 |
Why?
|
| Fistula | 1 | 2014 | 42 | 0.120 |
Why?
|
| Drug Substitution | 1 | 2014 | 27 | 0.110 |
Why?
|
| Radiation Protection | 1 | 2014 | 27 | 0.110 |
Why?
|
| Endoscopy | 3 | 2013 | 352 | 0.110 |
Why?
|
| Postoperative Period | 3 | 2016 | 301 | 0.110 |
Why?
|
| Oxides | 1 | 2014 | 43 | 0.110 |
Why?
|
| Aminosalicylic Acid | 1 | 2013 | 1 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 317 | 0.110 |
Why?
|
| Calcineurin | 1 | 2013 | 20 | 0.110 |
Why?
|
| Intestinal Obstruction | 3 | 2006 | 89 | 0.110 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 123 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 324 | 0.110 |
Why?
|
| Carbon | 1 | 2014 | 90 | 0.110 |
Why?
|
| Probiotics | 2 | 2008 | 89 | 0.110 |
Why?
|
| Cholangitis | 1 | 1993 | 19 | 0.110 |
Why?
|
| Mucous Membrane | 1 | 2013 | 83 | 0.110 |
Why?
|
| Pulmonary Embolism | 1 | 1996 | 232 | 0.110 |
Why?
|
| Vaginal Fistula | 1 | 1993 | 5 | 0.110 |
Why?
|
| Ciprofloxacin | 1 | 2013 | 29 | 0.110 |
Why?
|
| Observer Variation | 4 | 2018 | 614 | 0.110 |
Why?
|
| Occupational Exposure | 1 | 2014 | 87 | 0.110 |
Why?
|
| Enteritis | 1 | 2013 | 21 | 0.110 |
Why?
|
| Methyltransferases | 3 | 2011 | 192 | 0.110 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1992 | 18 | 0.100 |
Why?
|
| Consensus | 2 | 2022 | 366 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2017 | 413 | 0.100 |
Why?
|
| Defecation | 2 | 2009 | 23 | 0.100 |
Why?
|
| Gastritis | 1 | 2013 | 36 | 0.100 |
Why?
|
| Sickness Impact Profile | 2 | 2011 | 26 | 0.100 |
Why?
|
| Body Weight | 1 | 2013 | 453 | 0.100 |
Why?
|
| Sigmoid Diseases | 1 | 1992 | 4 | 0.100 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 1992 | 6 | 0.100 |
Why?
|
| Abatacept | 1 | 2012 | 86 | 0.100 |
Why?
|
| Guanine Nucleotides | 1 | 2011 | 14 | 0.100 |
Why?
|
| Bacterial Infections | 2 | 2006 | 184 | 0.100 |
Why?
|
| Thionucleotides | 1 | 2011 | 55 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 149 | 0.090 |
Why?
|
| Phenotype | 5 | 2021 | 2457 | 0.090 |
Why?
|
| Cytomegalovirus | 1 | 2011 | 79 | 0.090 |
Why?
|
| Proto-Oncogenes | 1 | 2011 | 61 | 0.090 |
Why?
|
| Immunoconjugates | 1 | 2012 | 114 | 0.090 |
Why?
|
| Attitude | 1 | 2012 | 130 | 0.090 |
Why?
|
| Age Factors | 4 | 2007 | 1880 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 2677 | 0.090 |
Why?
|
| Odds Ratio | 5 | 2003 | 682 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2002 | 54 | 0.090 |
Why?
|
| Carcinoma | 2 | 1995 | 438 | 0.090 |
Why?
|
| Capsules | 6 | 2002 | 37 | 0.090 |
Why?
|
| Patient Acuity | 2 | 2020 | 34 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 644 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 2011 | 150 | 0.090 |
Why?
|
| Liver | 3 | 2011 | 1211 | 0.090 |
Why?
|
| Reference Values | 2 | 2018 | 662 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2001 | 90 | 0.090 |
Why?
|
| Analysis of Variance | 4 | 2002 | 899 | 0.090 |
Why?
|
| Writing | 1 | 2010 | 29 | 0.090 |
Why?
|
| Mexico | 1 | 2010 | 70 | 0.090 |
Why?
|
| Interleukin-10 | 2 | 2000 | 155 | 0.090 |
Why?
|
| Editorial Policies | 1 | 2010 | 34 | 0.090 |
Why?
|
| Leukemia, Myeloid | 3 | 1995 | 249 | 0.080 |
Why?
|
| Cross-Cultural Comparison | 1 | 2009 | 34 | 0.080 |
Why?
|
| Folic Acid Deficiency | 1 | 1989 | 7 | 0.080 |
Why?
|
| Reoperation | 1 | 2012 | 605 | 0.080 |
Why?
|
| Photopheresis | 1 | 2009 | 12 | 0.080 |
Why?
|
| Folic Acid | 1 | 1989 | 63 | 0.080 |
Why?
|
| Rad51 Recombinase | 2 | 2021 | 81 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2000 | 100 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 1732 | 0.080 |
Why?
|
| Clinical Protocols | 2 | 2004 | 158 | 0.080 |
Why?
|
| Canada | 1 | 2009 | 208 | 0.080 |
Why?
|
| Ghrelin | 1 | 2009 | 29 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 3 | 2015 | 263 | 0.080 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2009 | 60 | 0.080 |
Why?
|
| Spiro Compounds | 1 | 2009 | 26 | 0.080 |
Why?
|
| Carrier Proteins | 2 | 2003 | 679 | 0.080 |
Why?
|
| Parenteral Nutrition | 2 | 1986 | 63 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2009 | 244 | 0.080 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2008 | 42 | 0.080 |
Why?
|
| Autoimmunity | 1 | 2010 | 169 | 0.080 |
Why?
|
| Chromosome Mapping | 4 | 2006 | 1074 | 0.080 |
Why?
|
| Feasibility Studies | 3 | 2007 | 785 | 0.080 |
Why?
|
| Body Composition | 1 | 2009 | 71 | 0.080 |
Why?
|
| Muscular Atrophy | 1 | 2009 | 46 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 168 | 0.080 |
Why?
|
| Immunoglobulin G | 2 | 2001 | 469 | 0.080 |
Why?
|
| Wine | 1 | 2008 | 6 | 0.080 |
Why?
|
| Interferon-beta | 1 | 2009 | 126 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 2 | 2016 | 303 | 0.080 |
Why?
|
| Haplotypes | 2 | 2008 | 637 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2009 | 114 | 0.080 |
Why?
|
| Preventive Medicine | 1 | 2008 | 18 | 0.080 |
Why?
|
| Psychology, Social | 1 | 2008 | 9 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1670 | 0.080 |
Why?
|
| Curcumin | 1 | 2008 | 18 | 0.080 |
Why?
|
| Video Recording | 3 | 2015 | 203 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2010 | 212 | 0.070 |
Why?
|
| Taste | 1 | 2008 | 28 | 0.070 |
Why?
|
| Glycoproteins | 1 | 1989 | 235 | 0.070 |
Why?
|
| Rifamycins | 1 | 2007 | 6 | 0.070 |
Why?
|
| Tablets | 1 | 2009 | 125 | 0.070 |
Why?
|
| Transcriptome | 1 | 2013 | 661 | 0.070 |
Why?
|
| Cisapride | 1 | 2007 | 4 | 0.070 |
Why?
|
| Domperidone | 1 | 2007 | 8 | 0.070 |
Why?
|
| Growth | 1 | 2007 | 43 | 0.070 |
Why?
|
| HCT116 Cells | 2 | 2021 | 156 | 0.070 |
Why?
|
| Antifoaming Agents | 1 | 2007 | 1 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 74 | 0.070 |
Why?
|
| Leukocyte Count | 3 | 2003 | 224 | 0.070 |
Why?
|
| Digestive System Physiological Phenomena | 1 | 2007 | 4 | 0.070 |
Why?
|
| Nutritional Requirements | 1 | 2007 | 17 | 0.070 |
Why?
|
| Taxes | 1 | 2007 | 3 | 0.070 |
Why?
|
| Food Service, Hospital | 1 | 2007 | 4 | 0.070 |
Why?
|
| Salicylates | 2 | 1999 | 25 | 0.070 |
Why?
|
| Vaccination | 1 | 2009 | 279 | 0.070 |
Why?
|
| Tumor Necrosis Factors | 1 | 2007 | 14 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 1989 | 334 | 0.070 |
Why?
|
| Cyclophosphamide | 3 | 1996 | 301 | 0.070 |
Why?
|
| Mass Screening | 2 | 2008 | 647 | 0.070 |
Why?
|
| Gases | 1 | 2007 | 30 | 0.070 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2006 | 8 | 0.070 |
Why?
|
| Gastrointestinal Transit | 1 | 2007 | 19 | 0.070 |
Why?
|
| Organizations | 1 | 2007 | 17 | 0.070 |
Why?
|
| Narration | 1 | 2007 | 17 | 0.070 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2006 | 10 | 0.070 |
Why?
|
| Computers, Handheld | 1 | 2007 | 33 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 182 | 0.070 |
Why?
|
| Cytotoxins | 1 | 1986 | 16 | 0.070 |
Why?
|
| Pregnancy Rate | 1 | 2006 | 21 | 0.070 |
Why?
|
| Preoperative Care | 1 | 1989 | 395 | 0.070 |
Why?
|
| Intestinal Perforation | 1 | 2007 | 36 | 0.070 |
Why?
|
| Health Facilities | 1 | 2007 | 39 | 0.070 |
Why?
|
| Metronidazole | 2 | 2000 | 26 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 376 | 0.070 |
Why?
|
| Longitudinal Studies | 3 | 2000 | 1082 | 0.070 |
Why?
|
| Constipation | 1 | 2007 | 64 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2004 | 1497 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 33 | 0.070 |
Why?
|
| Adsorption | 1 | 2006 | 53 | 0.070 |
Why?
|
| Medical Records | 1 | 2007 | 120 | 0.070 |
Why?
|
| Intestinal Absorption | 1 | 2007 | 125 | 0.070 |
Why?
|
| Energy Intake | 1 | 2006 | 99 | 0.070 |
Why?
|
| Endoscopy, Digestive System | 3 | 2001 | 69 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2006 | 103 | 0.070 |
Why?
|
| North America | 3 | 2014 | 188 | 0.070 |
Why?
|
| Sample Size | 1 | 2006 | 125 | 0.070 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1986 | 16 | 0.070 |
Why?
|
| Helicobacter Infections | 1 | 2006 | 37 | 0.070 |
Why?
|
| Vibrio parahaemolyticus | 1 | 2005 | 2 | 0.070 |
Why?
|
| Helicobacter pylori | 1 | 2006 | 37 | 0.070 |
Why?
|
| Alaska | 1 | 2005 | 20 | 0.070 |
Why?
|
| Sirolimus | 1 | 2007 | 162 | 0.070 |
Why?
|
| Ostreidae | 1 | 2005 | 3 | 0.070 |
Why?
|
| Health Education | 1 | 2006 | 105 | 0.060 |
Why?
|
| Jews | 2 | 2003 | 42 | 0.060 |
Why?
|
| Regression Analysis | 4 | 2010 | 591 | 0.060 |
Why?
|
| Integrin alpha Chains | 1 | 2005 | 16 | 0.060 |
Why?
|
| Bacterial Toxins | 1 | 1986 | 114 | 0.060 |
Why?
|
| Emotions | 1 | 2009 | 354 | 0.060 |
Why?
|
| Patient Care | 1 | 2007 | 102 | 0.060 |
Why?
|
| Mice | 4 | 2024 | 11858 | 0.060 |
Why?
|
| Recombinant Proteins | 4 | 2000 | 1008 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2006 | 66 | 0.060 |
Why?
|
| Pancreatitis | 1 | 1986 | 86 | 0.060 |
Why?
|
| Viscera | 1 | 2005 | 18 | 0.060 |
Why?
|
| Illinois | 1 | 2007 | 485 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 728 | 0.060 |
Why?
|
| Laos | 1 | 2005 | 4 | 0.060 |
Why?
|
| Histocytochemistry | 2 | 2017 | 130 | 0.060 |
Why?
|
| Mesenteric Veins | 1 | 2005 | 34 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 1996 | 135 | 0.060 |
Why?
|
| Paclitaxel | 1 | 2007 | 474 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2010 | 2415 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1997 | 563 | 0.060 |
Why?
|
| Equipment Design | 1 | 2006 | 422 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2006 | 99 | 0.060 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2004 | 69 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2887 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2013 | 855 | 0.060 |
Why?
|
| Combined Modality Therapy | 4 | 1999 | 1704 | 0.060 |
Why?
|
| HLA-DRB1 Chains | 1 | 2004 | 25 | 0.060 |
Why?
|
| Pancreatic Diseases | 1 | 2024 | 53 | 0.060 |
Why?
|
| Mucoproteins | 1 | 2024 | 14 | 0.060 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2024 | 5 | 0.060 |
Why?
|
| Research Subjects | 1 | 2005 | 73 | 0.060 |
Why?
|
| Lymphocyte Subsets | 1 | 2024 | 66 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 160 | 0.060 |
Why?
|
| Absenteeism | 1 | 2004 | 10 | 0.060 |
Why?
|
| Lymphocyte Count | 1 | 2024 | 99 | 0.060 |
Why?
|
| Primary Health Care | 1 | 2007 | 352 | 0.060 |
Why?
|
| Linkage Disequilibrium | 2 | 2008 | 477 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2004 | 166 | 0.060 |
Why?
|
| Confidence Intervals | 3 | 1994 | 221 | 0.060 |
Why?
|
| Fever | 1 | 2004 | 127 | 0.060 |
Why?
|
| Bone Density | 1 | 2005 | 211 | 0.060 |
Why?
|
| Drainage | 1 | 2004 | 165 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2004 | 417 | 0.060 |
Why?
|
| Fibroblast Growth Factor 10 | 1 | 2003 | 7 | 0.050 |
Why?
|
| Exercise | 1 | 2007 | 328 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 848 | 0.050 |
Why?
|
| Risk | 3 | 2011 | 657 | 0.050 |
Why?
|
| Probability | 1 | 2004 | 351 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2023 | 56 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 399 | 0.050 |
Why?
|
| Infant | 1 | 2010 | 3189 | 0.050 |
Why?
|
| Etanercept | 2 | 2001 | 33 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2006 | 286 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2006 | 776 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 754 | 0.050 |
Why?
|
| Therapeutic Equivalency | 1 | 2022 | 16 | 0.050 |
Why?
|
| Informed Consent | 1 | 2005 | 275 | 0.050 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1982 | 14 | 0.050 |
Why?
|
| Antibodies, Antinuclear | 3 | 2007 | 84 | 0.050 |
Why?
|
| Age of Onset | 4 | 2007 | 318 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 374 | 0.050 |
Why?
|
| Syndrome | 1 | 2003 | 450 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 256 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2022 | 64 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 983 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 778 | 0.050 |
Why?
|
| Patient Compliance | 4 | 2007 | 230 | 0.050 |
Why?
|
| Survival Rate | 3 | 2011 | 1899 | 0.050 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2002 | 18 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2024 | 354 | 0.050 |
Why?
|
| Sex Factors | 1 | 2005 | 1075 | 0.050 |
Why?
|
| Plasma Exchange | 1 | 2002 | 30 | 0.050 |
Why?
|
| Lod Score | 4 | 2006 | 152 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 72 | 0.050 |
Why?
|
| Bradycardia | 1 | 2021 | 40 | 0.050 |
Why?
|
| Ku Autoantigen | 1 | 2021 | 12 | 0.050 |
Why?
|
| Frameshift Mutation | 1 | 2001 | 51 | 0.050 |
Why?
|
| Cyclosporins | 1 | 2001 | 58 | 0.050 |
Why?
|
| Aftercare | 1 | 2022 | 88 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 283 | 0.050 |
Why?
|
| Folic Acid Antagonists | 1 | 2000 | 17 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 1999 | 305 | 0.050 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1981 | 186 | 0.050 |
Why?
|
| Peristalsis | 1 | 2000 | 10 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2021 | 176 | 0.040 |
Why?
|
| Suppositories | 1 | 2000 | 3 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2021 | 78 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 3253 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 166 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2013 | 521 | 0.040 |
Why?
|
| Decision Making | 1 | 2006 | 671 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 1986 | 901 | 0.040 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2000 | 65 | 0.040 |
Why?
|
| Genetic Markers | 3 | 2013 | 476 | 0.040 |
Why?
|
| Salvage Therapy | 2 | 2013 | 230 | 0.040 |
Why?
|
| Data Collection | 2 | 1999 | 377 | 0.040 |
Why?
|
| Gene Expression | 1 | 2024 | 1309 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2021 | 269 | 0.040 |
Why?
|
| Interleukin-11 | 1 | 1999 | 20 | 0.040 |
Why?
|
| Suture Techniques | 1 | 2000 | 144 | 0.040 |
Why?
|
| Cutaneous Fistula | 1 | 1999 | 11 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 303 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 1452 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 486 | 0.040 |
Why?
|
| Electromyography | 1 | 1999 | 195 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 1996 | 889 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 326 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 1284 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2024 | 699 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1998 | 65 | 0.040 |
Why?
|
| Health Services | 1 | 1999 | 57 | 0.040 |
Why?
|
| Proctocolitis | 1 | 1998 | 3 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1998 | 47 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2006 | 1380 | 0.040 |
Why?
|
| Reference Standards | 1 | 2018 | 144 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 1998 | 296 | 0.040 |
Why?
|
| Lipopolysaccharides | 2 | 2014 | 295 | 0.040 |
Why?
|
| Epistasis, Genetic | 1 | 1998 | 90 | 0.040 |
Why?
|
| Breast Neoplasms | 3 | 1996 | 3022 | 0.040 |
Why?
|
| Cost of Illness | 1 | 1998 | 149 | 0.040 |
Why?
|
| Transfection | 2 | 2010 | 909 | 0.040 |
Why?
|
| Monitoring, Ambulatory | 1 | 1997 | 32 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 60 | 0.040 |
Why?
|
| Constriction, Pathologic | 2 | 2006 | 222 | 0.040 |
Why?
|
| Fatty Acids, Volatile | 1 | 1997 | 32 | 0.040 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 1997 | 34 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 559 | 0.030 |
Why?
|
| Comorbidity | 1 | 2000 | 953 | 0.030 |
Why?
|
| Quinolines | 1 | 1997 | 86 | 0.030 |
Why?
|
| Interleukin-3 | 1 | 1996 | 36 | 0.030 |
Why?
|
| International Agencies | 1 | 2016 | 34 | 0.030 |
Why?
|
| Diphenhydramine | 1 | 1996 | 17 | 0.030 |
Why?
|
| Occludin | 1 | 2016 | 66 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 86 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2016 | 101 | 0.030 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 1996 | 21 | 0.030 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2016 | 70 | 0.030 |
Why?
|
| Histamine H1 Antagonists | 1 | 1996 | 40 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 2016 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 111 | 0.030 |
Why?
|
| Prostaglandin Antagonists | 1 | 1995 | 7 | 0.030 |
Why?
|
| Proteins | 1 | 2001 | 787 | 0.030 |
Why?
|
| Hypertension | 1 | 2021 | 747 | 0.030 |
Why?
|
| Databases, Factual | 1 | 1999 | 866 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 1996 | 178 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 205 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 1996 | 105 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 163 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 258 | 0.030 |
Why?
|
| NF-kappa B | 2 | 2013 | 469 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 151 | 0.030 |
Why?
|
| Phytohemagglutinins | 1 | 2014 | 21 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2017 | 3404 | 0.030 |
Why?
|
| Israel | 1 | 2014 | 57 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 466 | 0.030 |
Why?
|
| Minnesota | 1 | 1994 | 44 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 82 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 1994 | 59 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 2014 | 90 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2010 | 919 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1996 | 305 | 0.030 |
Why?
|
| Microspheres | 1 | 2014 | 108 | 0.030 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2013 | 16 | 0.030 |
Why?
|
| Dextran Sulfate | 1 | 2013 | 69 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2008 | 687 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2014 | 230 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 338 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2013 | 67 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 167 | 0.030 |
Why?
|
| Group Processes | 1 | 2013 | 31 | 0.030 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1993 | 25 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1994 | 301 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 198 | 0.030 |
Why?
|
| Tight Junctions | 1 | 2013 | 150 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 110 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2013 | 391 | 0.030 |
Why?
|
| Aneuploidy | 1 | 1992 | 57 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 294 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2012 | 147 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1995 | 360 | 0.020 |
Why?
|
| Suspensions | 1 | 2011 | 6 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2013 | 277 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 290 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2011 | 198 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2013 | 139 | 0.020 |
Why?
|
| Metagenome | 1 | 2012 | 105 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 131 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2012 | 251 | 0.020 |
Why?
|
| Tobacco Use Disorder | 1 | 2012 | 116 | 0.020 |
Why?
|
| Polymethacrylic Acids | 1 | 1990 | 3 | 0.020 |
Why?
|
| Chewing Gum | 1 | 1990 | 4 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 313 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 23 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 693 | 0.020 |
Why?
|
| Polyvinyls | 1 | 1990 | 17 | 0.020 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Patient Safety | 1 | 2013 | 219 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 726 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2010 | 101 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 234 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 139 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2014 | 457 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 272 | 0.020 |
Why?
|
| Methoxsalen | 1 | 2009 | 15 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1579 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 793 | 0.020 |
Why?
|
| Interferon beta-1a | 1 | 2009 | 18 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 689 | 0.020 |
Why?
|
| Photosensitizing Agents | 1 | 2009 | 51 | 0.020 |
Why?
|
| Motivation | 1 | 2012 | 296 | 0.020 |
Why?
|
| Cecum | 1 | 1989 | 73 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 270 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 1989 | 303 | 0.020 |
Why?
|
| Electrolytes | 1 | 1988 | 52 | 0.020 |
Why?
|
| Registries | 1 | 1993 | 808 | 0.020 |
Why?
|
| Midazolam | 1 | 2008 | 48 | 0.020 |
Why?
|
| Headache | 1 | 2009 | 73 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1801 | 0.020 |
Why?
|
| Rabbits | 2 | 2005 | 640 | 0.020 |
Why?
|
| Japan | 1 | 2008 | 304 | 0.020 |
Why?
|
| Anal Canal | 1 | 1988 | 88 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 1731 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1718 | 0.020 |
Why?
|
| Sacroiliac Joint | 1 | 2006 | 9 | 0.020 |
Why?
|
| Nod1 Signaling Adaptor Protein | 1 | 2006 | 2 | 0.020 |
Why?
|
| Emulsions | 1 | 1986 | 19 | 0.020 |
Why?
|
| Rectal Diseases | 1 | 2006 | 23 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 824 | 0.020 |
Why?
|
| Stomach Diseases | 1 | 2006 | 19 | 0.020 |
Why?
|
| Duodenal Diseases | 1 | 2006 | 23 | 0.020 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 27 | 0.020 |
Why?
|
| Uveitis | 1 | 2006 | 31 | 0.020 |
Why?
|
| JC Virus | 1 | 2005 | 5 | 0.020 |
Why?
|
| Influenza, Human | 1 | 2009 | 340 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2005 | 55 | 0.020 |
Why?
|
| Short Bowel Syndrome | 1 | 2005 | 38 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2011 | 2026 | 0.020 |
Why?
|
| Minority Groups | 1 | 2006 | 147 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 1985 | 92 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2005 | 82 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2004 | 64 | 0.010 |
Why?
|
| Intestine, Large | 1 | 1984 | 15 | 0.010 |
Why?
|
| Random Allocation | 1 | 2005 | 327 | 0.010 |
Why?
|
| Diverticulum, Colon | 1 | 1984 | 10 | 0.010 |
Why?
|
| Campylobacter Infections | 1 | 1984 | 12 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2007 | 450 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 1984 | 37 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 277 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 313 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 1243 | 0.010 |
Why?
|
| Physical Examination | 1 | 1984 | 150 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 600 | 0.010 |
Why?
|
| Software | 1 | 2007 | 669 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 2588 | 0.010 |
Why?
|
| Length of Stay | 2 | 1996 | 749 | 0.010 |
Why?
|
| Thyroxine | 1 | 1984 | 355 | 0.010 |
Why?
|
| Radiography | 1 | 1984 | 808 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 1691 | 0.010 |
Why?
|
| Clostridium Infections | 1 | 1984 | 125 | 0.010 |
Why?
|
| Blastomycosis | 1 | 1981 | 7 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2005 | 432 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2003 | 528 | 0.010 |
Why?
|
| Mycobacterium Infections | 1 | 1981 | 15 | 0.010 |
Why?
|
| Cellulitis | 1 | 1981 | 19 | 0.010 |
Why?
|
| Splenectomy | 1 | 1981 | 82 | 0.010 |
Why?
|
| Hepatitis | 1 | 1981 | 34 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 365 | 0.010 |
Why?
|
| Homozygote | 1 | 2001 | 200 | 0.010 |
Why?
|
| I-kappa B Proteins | 1 | 2000 | 54 | 0.010 |
Why?
|
| Abscess | 1 | 1981 | 94 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2001 | 114 | 0.010 |
Why?
|
| Injections | 1 | 2001 | 116 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2000 | 30 | 0.010 |
Why?
|
| Middle East | 1 | 2000 | 18 | 0.010 |
Why?
|
| Physical Chromosome Mapping | 1 | 2000 | 27 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2000 | 64 | 0.010 |
Why?
|
| Cytosine | 1 | 2001 | 130 | 0.010 |
Why?
|
| Heterozygote | 1 | 2001 | 373 | 0.010 |
Why?
|
| Family Health | 1 | 2000 | 162 | 0.010 |
Why?
|
| International Cooperation | 1 | 2000 | 127 | 0.010 |
Why?
|
| Lymphoma | 1 | 1981 | 266 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 352 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 740 | 0.010 |
Why?
|
| Pedigree | 1 | 2000 | 969 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1999 | 254 | 0.010 |
Why?
|
| Alleles | 1 | 2001 | 1137 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2395 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 2064 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 200 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 2329 | 0.010 |
Why?
|
| Leukotriene B4 | 1 | 1997 | 14 | 0.010 |
Why?
|
| Cell Line | 1 | 2001 | 2495 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1996 | 40 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 3024 | 0.010 |
Why?
|
| Blood Cells | 1 | 1996 | 33 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 1996 | 40 | 0.010 |
Why?
|
| Thiotepa | 1 | 1996 | 32 | 0.010 |
Why?
|
| Life Tables | 1 | 1996 | 47 | 0.010 |
Why?
|
| Premedication | 1 | 1996 | 57 | 0.010 |
Why?
|
| Thrombophlebitis | 1 | 1995 | 25 | 0.010 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1995 | 37 | 0.010 |
Why?
|
| Melphalan | 1 | 1996 | 98 | 0.010 |
Why?
|
| Karyotyping | 1 | 1995 | 252 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1996 | 293 | 0.010 |
Why?
|
| Insurance Selection Bias | 1 | 1995 | 1 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1981 | 799 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1996 | 284 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1995 | 47 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1996 | 549 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 1995 | 384 | 0.010 |
Why?
|
| Palliative Care | 1 | 1996 | 264 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 1995 | 204 | 0.010 |
Why?
|
| Genotype | 1 | 1998 | 1852 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 1996 | 1169 | 0.010 |
Why?
|
| Orosomucoid | 1 | 1991 | 1 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1981 | 2331 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 1988 | 62 | 0.000 |
Why?
|
| Cyclic AMP | 1 | 1988 | 277 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1993 | 2497 | 0.000 |
Why?
|
| Alanine Transaminase | 1 | 1985 | 72 | 0.000 |
Why?
|
| Aspartate Aminotransferases | 1 | 1985 | 75 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1985 | 132 | 0.000 |
Why?
|
| Bilirubin | 1 | 1985 | 131 | 0.000 |
Why?
|
| Blastomyces | 1 | 1981 | 3 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1983 | 740 | 0.000 |
Why?
|
| Skin | 1 | 1981 | 589 | 0.000 |
Why?
|